Array ( [0] => Applebot/0.1 [1] => facebookexternalhit/1.1 [2] => LinkedInBot/1.0 [3] => meta-externalagent/1.1 [4] => Amazonbot/0.1 [5] => BLEXBot/1.0 [6] => DotBot/1.2 [7] => Qwantbot/1.0_1997801 [8] => AhrefsBot/7.0 [9] => DataForSeoBot/1.0 [10] => MatchorySearch/1.3 [11] => WRTNBot/1.0 [12] => Sogou web spider/4.0 [13] => MojeekBot/0.11 [14] => Yeti/1.1 [15] => SeznamBot/4.0 [16] => SemrushBot-SI/0.97 [17] => MistralAI-User/1.0 [18] => Qwantbot/1.0 [19] => coccocbot-web/1.0 [20] => coccocbot-image/1.0 [21] => PlagAwareBot/3.2 [22] => Barkrowler/0.9 [23] => AwarioSmartBot/1.0 [24] => PetalBot [25] => archive.org_bot [26] => Iframely/1.3.1 [27] => LogRocket-AssetCacher [28] => Slackbot 1.0 [29] => node-fetch/1.0 [30] => MJ12bot/v1.4.8 [31] => MJ12bot/v2.0.0 [32] => Timpibot/0.9 [33] => AwarioBot/1.0 [34] => MJ12bot/v2.0.1 [35] => Qwantbot/1.0_2850318 [36] => SiteAuditBot/0.97 [37] => Scrapy/2.11.2 [38] => CCBot/2.0 [39] => MJ12bot/v2.0.2 [40] => Scrapy/2.13.3 [41] => WordPress/6.8.3 [42] => MJ12bot/v2.0.4 [43] => SemrushBot/7~bl [44] => Qwairy-Bot/1.0 [45] => Embedly/0.2 [46] => GeedoProductSearch [47] => SemrushBot [48] => vkShare [49] => inkrich [50] => Discordbot/2.0 [51] => IbouBot/1.0 [52] => trafilatura/1.6.3 [53] => AnsehnBot/1.0 [54] => WP-URLDetails/6.8.3 [55] => HubSpot Crawler [56] => ShapBot/0.1.0 [57] => udu/1.6.5 [58] => aiohttp/3.13.1 [59] => l9scan/2.0 [60] => Trident/5.0 [61] => SmartBotCrawler/1.0 [62] => ) The user agent is not in the allowed list.Array ( [0] => pingbot/2.0 [1] => Googlebot/2.1 [2] => ChatGPT-User/1.0 [3] => PerplexityBot/1.0 [4] => OAI-SearchBot/1.0 [5] => GPTBot/1.2 [6] => Perplexity-User/1.0 [7] => YandexBot/3.0 [8] => YandexFavicons/1.0 [9] => AdsBot-Google-Mobile [10] => AdsBot-Google [11] => Gemini-Deep-Research [12] => DuckAssistBot/1.1 [13] => DuckDuckBot/1.1 [14] => GoogleOther [15] => YandexRenderResourcesBot/1.0 [16] => YandexImages/3.0 [17] => DuckAssistBot/1.2 [18] => Baiduspider/2.0 [19] => Baiduspider-render/2.0 [20] => bingbot/2.0 [21] => YandexUserproxy [22] => Pingdom.com_bot_version_1.4_ [23] => GPTBot/1.3 [24] => PingdomPageSpeed/1.0 [25] => YandexMobileBot/3.0 [26] => OAI-SearchBot/1.3 [27] => ClaudeBot/1.0 [28] => OAI-SearchBot/1.3 [29] => ) The user agent is an allowed/known agent.
Chlorpheniramine Maleate Market Size & Forecasts 2026-2035, By Segments (Distribution Channel, Application, Formulation Type), Growth Opportunities, Innovation Landscape, Regulatory Shifts, Strategic Regional Insights (U.S., Japan, China, South Korea, UK, Germany, France), and Competitive Dynamics (Pfizer, Sanofi, Novartis, GlaxoSmithKline, Merck)
Market Size and Growth Outlook
Base Year Value (2025)
USD 512.55 Million
CAGR (2026-2035)
5.2%
Forecast Year Value (2035)
USD 850.93 Million
Historical Data Period
2022-2025
Largest Region
North America
Forecast Period
2026-2035
Key Takeaways
- North America region held over 41.2% market share in 2025, due to strong pharmaceutical infrastructure.
- Asia Pacific region will observe over 6.8% CAGR between 2026 and 2035, propelled by rising allergy prevalence and generic drug demand.
- In 2025, the retail pharmacies segment held a 42.23% share of the market, propelled by broad accessibility for over-the-counter purchases.
- In 2025, the allergic rhinitis (hay fever) segment accounted for a 40.95% of the chlorpheniramine maleate market, fueled by rising incidence and awareness of seasonal allergies.
- The tablets segment held a market share of over 41.2% in 2025, driven by cost-effectiveness and convenience for daily adherence.
- The leading players in the chlorpheniramine maleate market include Pfizer (USA), Sanofi (France), Novartis (Switzerland), GlaxoSmithKline (UK), Merck (USA), Teva (Israel), Mylan (USA), Sun Pharma (India), Cipla (India), Lupin (India).
Market Growth Drivers and Industry Trends
Increasing Adoption of Chlorpheniramine Maleate in Pharmaceuticals
The chlorpheniramine maleate market is experiencing significant growth due to its increasing adoption in pharmaceutical formulations. As consumer awareness regarding allergy management rises, there is a growing demand for effective antihistamines. Leading pharmaceutical companies, such as Pfizer, have reported enhanced product lines featuring chlorpheniramine maleate, catering to diverse consumer needs. This trend reflects a shift in consumer behavior towards seeking reliable over-the-counter solutions for allergy relief, fueled by rising incidences of allergic conditions. For established players, this presents an opportunity to expand their product portfolios while new entrants can explore niche markets focusing on innovative formulations that meet evolving consumer preferences.
Technological Advancements in Drug Formulation & Delivery
Innovations in drug formulation and delivery systems are reshaping the chlorpheniramine maleate market. Advances in nanotechnology and sustained-release formulations are enabling enhanced bioavailability and patient compliance. Companies like GlaxoSmithKline are investing in research to develop novel delivery methods that not only improve efficacy but also reduce side effects, thus appealing to a broader patient demographic. This technological evolution not only fosters competitive differentiation for established firms but also lowers entry barriers for startups that can leverage these advancements to create unique product offerings. As the market evolves, the emphasis on patient-centric solutions will likely drive further innovation in drug delivery technologies.
Regulatory Approvals for Antihistamines
The chlorpheniramine maleate market is significantly influenced by regulatory approvals that facilitate the introduction of new antihistamine products. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), are streamlining approval processes for safe and effective allergy medications, which encourages both innovation and market entry. Recent approvals for combination therapies that include chlorpheniramine maleate highlight the regulatory landscape's responsiveness to consumer needs. This environment not only benefits established pharmaceutical companies looking to diversify their offerings but also presents strategic opportunities for new entrants seeking to navigate the regulatory framework effectively. With ongoing regulatory support, the market is poised for continued evolution, reflecting a commitment to improving public health outcomes.
| Growth Driver Assessment Framework | |||||
| Growth Driver | Impact On CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing Adoption of Chlorpheniramine Maleate in Pharmaceuticals | 2.00% | Short term (≤ 2 yrs) | North America, Europe (spillover: Asia Pacific) | Medium | Fast |
| Technological Advancements in Drug Formulation & Delivery | 1.80% | Medium term (2–5 yrs) | Europe, North America (spillover: Asia Pacific) | Low | Moderate |
| Regulatory Approvals for Antihistamines | 1.40% | Long term (5+ yrs) | North America, Europe (spillover: MEA) | High | Moderate |
Unlock insights tailored to your business with our bespoke market research solutions - Click to get your customized report now!
Intellectual Property Challenges
The chlorpheniramine maleate market faces significant intellectual property challenges that hinder innovation and market entry for new players. Patent expirations have led to a surge in generic competition, which, while beneficial for consumers through lower prices, places immense pressure on established manufacturers to differentiate their products. For instance, according to the U.S. Patent and Trademark Office, several key patents for chlorpheniramine formulations have recently expired, allowing generic producers to capture market share rapidly. This shift not only reduces profit margins for original developers but also discourages investment in research and development for new formulations or delivery methods. Consequently, established companies must navigate a landscape where differentiation becomes increasingly difficult, while new entrants struggle to secure a foothold against established generics.
Market Access Limitations
Another critical restraint impacting the chlorpheniramine maleate market is the complex market access landscape shaped by varying regulatory frameworks across regions. Different countries impose distinct approval processes and pricing regulations, which can significantly delay product launches and limit market entry for both domestic and international players. For example, the European Medicines Agency (EMA) has stringent requirements for clinical data that can prolong the time to market, creating barriers for companies looking to introduce innovative formulations. This regulatory fragmentation not only complicates strategic planning for market participants but also leads to increased operational costs. As a result, companies may prioritize regions with more favorable regulations, potentially neglecting emerging markets with unmet needs. Looking ahead, these market access challenges are likely to persist, compelling stakeholders to adopt more agile strategies to navigate the evolving regulatory terrain.
Regional Demand Dynamics
Largest Region
North America
41.2% Market Share in 2025
North America Market Statistics:
North America represented more than 41.2% of the global chlorpheniramine maleate market in 2025, establishing itself as the largest and fastest-growing region. This dominance can be attributed to the region's strong pharmaceutical infrastructure, which fosters innovation and efficiency in drug development and distribution. The robust healthcare system, coupled with increasing consumer awareness and demand for effective allergy medications, has catalyzed growth in this sector. Additionally, shifting consumer preferences towards over-the-counter medications and advancements in digital health solutions have enhanced accessibility and convenience for consumers. Reports from the Food and Drug Administration (FDA) highlight ongoing regulatory support for antihistamines, further solidifying North America's leadership in the chlorpheniramine maleate market. Looking ahead, the region presents significant opportunities, driven by continued investment in pharmaceutical research and development, alongside a growing emphasis on patient-centered healthcare solutions.
The United States anchors the North American chlorpheniramine maleate market, leveraging its advanced healthcare ecosystem and significant R&D investments. The country's strong pharmaceutical infrastructure enables rapid product development and regulatory approval processes, which are crucial for meeting the increasing demand for allergy relief solutions. For instance, the Pharmaceutical Research and Manufacturers of America (PhRMA) reports that U.S. companies invest more than $80 billion annually in R&D, fostering innovation in allergy medications. Moreover, the competitive landscape is characterized by strategic partnerships and mergers among key players, enhancing their market offerings. This dynamic environment positions the U.S. as a vital contributor to the overall growth of the chlorpheniramine maleate market in North America, reinforcing the region's attractiveness for investors.
Canada also plays a pivotal role in the North American chlorpheniramine maleate market, benefiting from a supportive regulatory framework and a growing emphasis on public health initiatives. The Canadian government has prioritized access to affordable medications, which has facilitated the introduction of various antihistamine products, including chlorpheniramine maleate. According to Health Canada, the increasing incidence of allergies among the population has led to heightened demand for effective over-the-counter solutions. This trend is further supported by a culturally diverse population that drives varied consumer preferences, necessitating a broad range of product offerings. As Canada continues to enhance its healthcare policies and promote public health, it reinforces the overall growth trajectory of the chlorpheniramine maleate market in North America, presenting strategic opportunities for stakeholders.
Asia Pacific Market Analysis:
Asia Pacific emerged as the fastest-growing region in the chlorpheniramine maleate market, registering a robust CAGR of 6.8%. This growth is primarily driven by the rising prevalence of allergies and an increasing demand for generic drugs, which are more affordable and accessible to a broader population. The region's significant investment in healthcare infrastructure and the expansion of pharmaceutical companies aiming to meet the surging demand for allergy medications further amplify its market potential. Additionally, shifts in consumer preferences towards over-the-counter medications, combined with a heightened awareness of allergy-related health issues, have propelled market dynamics. Recent reports from the World Health Organization highlight that the Asia Pacific region is experiencing a notable increase in allergic conditions, reinforcing the urgent need for effective treatments like chlorpheniramine maleate. As healthcare continues to evolve, the region presents substantial opportunities for stakeholders in the chlorpheniramine maleate market, driven by both consumer demand and supportive regulatory frameworks.
Japan plays a pivotal role in the chlorpheniramine maleate market within Asia Pacific, characterized by its advanced healthcare system and a growing aging population that increasingly suffers from allergies. The rising allergy prevalence, particularly among the elderly, has led to a surge in demand for effective antihistamines. Japanese consumers exhibit a strong preference for trusted, established brands, which drives pharmaceutical companies to innovate and enhance their product offerings. Recent initiatives by the Ministry of Health, Labour and Welfare to promote generic medications align with the growing consumer shift towards cost-effective healthcare solutions. Consequently, Japan's strategic focus on improving access to allergy treatments positions it as a critical player in the regional chlorpheniramine maleate market, presenting significant opportunities for growth and expansion.
China stands as another major contributor to the chlorpheniramine maleate market in Asia Pacific, fueled by its vast population and increasing awareness of allergy management. The rising prevalence of respiratory allergies, particularly in urban areas, has heightened consumer demand for effective antihistamines. The Chinese government's recent policies aimed at enhancing healthcare access and affordability have catalyzed the growth of the generic drug market, making chlorpheniramine maleate more accessible to consumers. Moreover, the rapid digital transformation in China's pharmaceutical sector has enabled companies to leverage e-commerce platforms to reach a broader audience, enhancing market penetration. As a result, China's evolving healthcare landscape, combined with its focus on affordability and accessibility, reinforces its strategic importance in the chlorpheniramine maleate market and offers promising avenues for future growth.
Europe Market Trends:
Europe held a commanding share in the chlorpheniramine maleate market, driven by a combination of robust healthcare infrastructure and increasing consumer awareness regarding allergy treatments. The region's significance is underscored by a heightened focus on health and wellness, leading to a surge in demand for effective antihistamines. Notably, the European Medicines Agency (EMA) has been proactive in updating regulations, ensuring safety and efficacy, which aligns with consumer preferences for reliable pharmaceutical products. This regulatory environment, coupled with advancements in digital health technologies, has facilitated streamlined supply chains and enhanced accessibility. As a result, Europe presents substantial opportunities for growth, particularly as sustainability initiatives become more integrated into pharmaceutical practices.
Germany plays a pivotal role in the chlorpheniramine maleate market, characterized by its strong pharmaceutical sector and innovative research capabilities. The country has seen a notable increase in consumer demand for over-the-counter allergy medications, spurred by rising pollen counts and changing climate conditions. According to the Federal Institute for Drugs and Medical Devices (BfArM), the shift towards self-medication has propelled sales of antihistamines, including chlorpheniramine maleate. This trend is further supported by a competitive landscape that encourages product innovation and differentiation. Germany’s strategic position within Europe enhances its potential as a hub for chlorpheniramine maleate distribution, directly benefiting the regional market.
France also holds a significant position in the chlorpheniramine maleate market, driven by a cultural inclination towards preventive healthcare and self-care solutions. The French population's increasing preference for accessible allergy treatments has led to a rise in the availability of chlorpheniramine maleate in pharmacies and online platforms. The French National Agency for the Safety of Medicines and Health Products (ANSM) has been instrumental in promoting awareness about allergy management, which has positively influenced consumer adoption rates. This cultural shift, combined with a growing emphasis on digital healthcare solutions, positions France as a key player in the European chlorpheniramine maleate landscape, further enhancing the region's overall market potential.
| Regional Market Attractiveness & Strategic Fit Matrix | |||||
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub | Advanced | Developing | Advanced | Developing | Developing |
| Cost-Sensitive Region | Low | High | Medium | High | High |
| Regulatory Environment | Supportive | Neutral | Supportive | Neutral | Neutral |
| Demand Drivers | Moderate | Strong | Moderate | Moderate | Moderate |
| Development Stage | Developed | Developing | Developed | Developing | Emerging |
| Adoption Rate | High | Medium | High | Medium | Medium |
| New Entrants / Startups | Dense | Moderate | Dense | Moderate | Moderate |
| Macro Indicators | Strong | Strong | Stable | Stable | Stable |
Segment Leadership and Growth Trends
Analysis by Distribution Channel
The chlorpheniramine maleate market for distribution channels is led by retail pharmacies, which captured over 42.23% share in 2025. This dominance is attributed to broad accessibility for over-the-counter purchases, making it easier for consumers to obtain necessary medications without prescription barriers. The convenience of retail pharmacies aligns with consumer preferences for immediate access to treatments, particularly in urban areas where these outlets are plentiful. According to the National Association of Boards of Pharmacy, the increase in retail pharmacy locations has significantly enhanced distribution efficiency. This segment creates strategic advantages for established firms through extensive shelf presence, while emerging players can leverage e-commerce partnerships to reach a wider audience. With the continued trend towards self-medication and the expansion of pharmacy services, this segment is expected to remain vital in the near to medium term.
Analysis by Application
In the chlorpheniramine maleate market, the allergic rhinitis (hay fever) segment represented more than 40.95% of the market share in 2025. This leadership is driven by the rising incidence and awareness of seasonal allergies, prompting consumers to seek effective relief options. Increased public health campaigns, such as those by the American Academy of Allergy, Asthma & Immunology, have heightened awareness around allergy management, further boosting demand. The segment benefits from changing consumer behaviors that prioritize proactive health management, allowing established companies to innovate product formulations while new entrants can capitalize on niche marketing strategies. Given the ongoing rise in allergy prevalence and the growing focus on preventive healthcare, this segment is poised to maintain its significance moving forward.
Analysis by Formulation Type
The chlorpheniramine maleate market for formulation types is dominated by tablets, holding a commanding 41.2% share in 2025. This segment's leadership stems from the cost-effectiveness and convenience of tablets, which enhance daily adherence to treatment regimens. The preference for solid dosage forms, as highlighted by the World Health Organization, reflects a broader trend towards user-friendly medication formats that facilitate patient compliance. This segment offers established firms the opportunity to refine their product offerings while enabling startups to introduce innovative tablet formulations that cater to specific consumer needs. As the demand for convenient and effective medication continues to grow, particularly among busy consumers, this segment is expected to remain relevant in the coming years.
| Report Segmentation | |
| Segment | Sub-Segment |
|---|---|
| Distribution Channel | Hospital pharmacies, Retail pharmacies, Online pharmacies |
| Application | Allergic, Allergic rhinitis (hay fever), Common cold, Other applications |
| Formulation Type | Injections, Tablets, Syrup, Other formulation types |
Read our Research ApproachCompetitive Landscape and Market Positioning
Company Profile
Business Overview Financial Highlights Product Landscape SWOT Analysis Recent Developments Company Heat Map Analysis
Key players in the chlorpheniramine maleate market include prominent pharmaceutical companies such as Pfizer, Sanofi, Novartis, GlaxoSmithKline, Merck, Teva, Mylan, Sun Pharma, Cipla, and Lupin. Each of these companies holds a significant position in the market, driven by their extensive research capabilities, established distribution networks, and strong brand recognition. Pfizer and Merck, for instance, leverage their robust portfolios to enhance market penetration, while Sanofi and Novartis focus on innovation and therapeutic advancements. The influence of these players is further underscored by their global presence and commitment to addressing consumer needs in allergy and cold-related treatments, making them pivotal in shaping market trends and consumer preferences.
The competitive landscape of the chlorpheniramine maleate market is characterized by dynamic strategic initiatives among the leading players. Companies are actively engaging in collaborations and partnerships to enhance their product offerings and expand their market reach. For example, innovative product launches and advancements in formulation technologies are being pursued to meet evolving consumer demands and regulatory standards. Additionally, investments in research and development are prevalent as firms seek to differentiate themselves through enhanced efficacy and safety profiles of their products. This environment fosters a culture of continuous improvement and responsiveness to market changes, thus reinforcing the competitive positioning of these key players.
Strategic / Actionable Recommendations for Regional Players
In North America, there is an opportunity for regional companies to enhance their market presence by exploring partnerships with healthcare providers and technology firms. Collaborations that focus on digital health solutions can facilitate better patient engagement and adherence to treatment protocols, ultimately driving sales growth.
In the Asia Pacific region, tapping into high-growth sub-segments such as pediatric formulations can provide avenues for expansion. Engaging in local alliances with distributors who understand regional market dynamics can also bolster distribution efficiency and consumer reach.
For players in Europe, responding to competitive initiatives through the development of value-added services, such as patient education programs, can strengthen brand loyalty. Additionally, leveraging advancements in biopharmaceutical technologies may lead to innovative formulations that cater to the specific needs of the European market.
| Competitive Dynamics and Strategic Insights | ||
| Assessment Parameter | Assigned Scale | Scale Justification |
|---|---|---|
| Market Concentration | Medium | The market features several key players, but no single entity dominates, allowing for moderate competition. |
| M&A Activity / Consolidation Trend | Moderate | There have been some strategic acquisitions, but overall consolidation remains moderate as companies seek to diversify portfolios. |
| Degree of Product Differentiation | Low | Products in this market are largely similar, with few unique formulations or delivery methods available. |
| Competitive Advantage Sustainability | Eroding | As generic alternatives proliferate, the competitive advantages of established brands are diminishing. |
| Innovation Intensity | Low | Innovation in formulations is limited, with most products focusing on cost reduction rather than new developments. |
| Customer Loyalty / Stickiness | Weak | Consumers often switch between brands based on price and availability, leading to low brand loyalty. |
| Vertical Integration Level | Low | Most companies operate in a fragmented manner, focusing on specific segments rather than full vertical integration. |
Frequently Asked Questions
How much revenue does the chlorpheniramine maleate market generate?
The market revenue for chlorpheniramine maleate is anticipated at USD 535.62 million in 2026.
What is the projected value of the chlorpheniramine maleate industry by 2035?
Chlorpheniramine Maleate Market size is anticipated to rise from USD 512.55 million in 2025 to USD 850.93 million by 2035, reflecting a CAGR surpassing 5.2% over the forecast horizon of 2026-2035.
In which region is the chlorpheniramine maleate industry most concentrated?
North America region held over 41.2% market share in 2025, due to strong pharmaceutical infrastructure.
Which area is showing the greatest surge in chlorpheniramine maleate sector?
Asia Pacific region will observe over 6.8% CAGR between 2026 and 2035, propelled by rising allergy prevalence and generic drug demand.
What share does retail pharmacies segment hold in the chlorpheniramine maleate sector as of 2025?
In 2025, the retail pharmacies segment held a 42.23% share of the market, propelled by broad accessibility for over-the-counter purchases.
Where is the allergic rhinitis (hay fever) segment seeing the strongest adoption within the chlorpheniramine maleate industry?
In 2025, the allergic rhinitis (hay fever) segment accounted for a 40.95% of the chlorpheniramine maleate market, fueled by rising incidence and awareness of seasonal allergies.
When did tablets sub-segment emerge as the largest sub-segment in the formulation type segment of chlorpheniramine maleate sector?
The tablets segment held a market share of over 41.2% in 2025, driven by cost-effectiveness and convenience for daily adherence.
What are the prominent companies operating in the chlorpheniramine maleate landscape?
The leading players in the chlorpheniramine maleate market include Pfizer (USA), Sanofi (France), Novartis (Switzerland), GlaxoSmithKline (UK), Merck (USA), Teva (Israel), Mylan (USA), Sun Pharma (India), Cipla (India), Lupin (India).
Our Clients
Why Choose Us
Specialized Expertise: Our team comprises industry experts with a deep understanding of your market segment. We bring specialized knowledge and experience that ensures our research and consulting services are tailored to your unique needs.
Customized Solutions: We understand that every client is different. That's why we offer customized research and consulting solutions designed specifically to address your challenges and capitalize on opportunities within your industry.
Proven Results: With a track record of successful projects and satisfied clients, we have demonstrated our ability to deliver tangible results. Our case studies and testimonials speak to our effectiveness in helping clients achieve their goals.
Cutting-Edge Methodologies: We leverage the latest methodologies and technologies to gather insights and drive informed decision-making. Our innovative approach ensures that you stay ahead of the curve and gain a competitive edge in your market.
Client-Centric Approach: Your satisfaction is our top priority. We prioritize open communication, responsiveness, and transparency to ensure that we not only meet but exceed your expectations at every stage of the engagement.
Continuous Innovation: We are committed to continuous improvement and staying at the forefront of our industry. Through ongoing learning, professional development, and investment in new technologies, we ensure that our services are always evolving to meet your evolving needs.
Value for Money: Our competitive pricing and flexible engagement models ensure that you get maximum value for your investment. We are committed to delivering high-quality results that help you achieve a strong return on your investment.
Select Licence Type
